Sarepta Accounts Payable from 2010 to 2024

SRPT Stock  USD 133.34  4.60  3.33%   
Sarepta Therapeutics Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable is likely to outpace its year average in 2024. Accounts Payable is the amount Sarepta Therapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Sarepta Therapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
1996-12-31
Previous Quarter
107.4 M
Current Value
118.8 M
Quarterly Volatility
35.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sarepta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sarepta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 61.8 M, Interest Expense of 23.1 M or Selling General Administrative of 475.9 M, as well as many indicators such as Price To Sales Ratio of 6.81, Dividend Yield of 0.0 or PTB Ratio of 6.7. Sarepta financial statements analysis is a perfect complement when working with Sarepta Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Sarepta Therapeutics Correlation against competitors.
For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Latest Sarepta Therapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Sarepta Therapeutics over the last few years. An accounting item on the balance sheet that represents Sarepta Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Sarepta Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Sarepta Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sarepta Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Sarepta Accounts Payable Regression Statistics

Arithmetic Mean55,278,127
Geometric Mean23,720,504
Coefficient Of Variation104.29
Mean Deviation47,761,752
Median29,690,000
Standard Deviation57,647,039
Sample Variance3323.2T
Range173.1M
R-Value0.89
Mean Square Error732.8T
R-Squared0.80
Slope11,495,098
Total Sum of Squares46524.5T

Sarepta Accounts Payable History

2024173.2 M
2023164.9 M
202295.9 M
202176.7 M
2020111.1 M
201968.1 M
201833.8 M

About Sarepta Therapeutics Financial Statements

Sarepta Therapeutics shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Sarepta Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Sarepta Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Sarepta Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable164.9 M173.2 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.